Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ai Ni

Showing results (101-110 of 108) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 108 results.
The Lancet. Haematology|May 22, 2019
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validationsJacob D Soumerai, Ai Ni, Mohamed Darif, et al.
Cancer|August 31, 2019
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancersMichael Offin, Daniel Feldman, Ai Ni, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphomaConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialBob T Li, Ronglai Shen, Darren Buonocore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingHira Rizvi, Francisco Sanchez-Vega, Konnor La, et al.
Cancer Cell|April 17, 2018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Tavi Nathanson, Hira Rizvi, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 11

Showing results (101-110 of 108) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 108 results.
The Lancet. Haematology|May 22, 2019
Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validationsJacob D Soumerai, Ai Ni, Mohamed Darif, et al.
Cancer|August 31, 2019
Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancersMichael Offin, Daniel Feldman, Ai Ni, et al.
European Journal of Cancer (Oxford, England : 1990)|January 14, 2020
Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphomaConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Blood Cancer Journal|July 18, 2020
Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie L Batlevi, Fushen Sha, Anna Alperovich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialBob T Li, Ronglai Shen, Darren Buonocore, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2018
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation SequencingHira Rizvi, Francisco Sanchez-Vega, Konnor La, et al.
Cancer Cell|April 17, 2018
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerMatthew D Hellmann, Tavi Nathanson, Hira Rizvi, et al.
The Lancet. Haematology|November 26, 2021
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trialJacob D Soumerai, Anthony R Mato, Ahmet Dogan, et al.
Pageof 11